We have developed a novel, highly efficient treatment of severe hetero- and homozygous familiar hypercholesterolemic patients. Low Density Lipoprotein (LDL) is eliminated by ex vivo immunoabsorption. The treatment is named Low Density Lipoprotein (LDL) apheresis. The method is being applied in several clinical centres around the world. LDL-apheresis paved the way for further applications in immunoadsorption apheresis in medicine.
Literature
W. Stoffel, H. Borberg, V. Greve (1981) Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolemia The Lancet, 1005-1007
W. Stoffel, W. Kahlke (1965) The transformation of phytol into 3,7,11,15-tetramethylhexadecanoic (phytanic) acid in Heredopathia atactica polyneuritiformis (Refsum's syndrome) Biochem. Biophys. Res. Comm., 19, 33-36
W. Stoffel (2009) The birth of LDL-apharesis